Scarica l'app Stockscreener
3.44
2.55%
-0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative
GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat
Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelHagopian Line - dars.gov.et
Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et
Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail
Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India
Galectin chairman converts $105.8 million debt to equity - Investing.com
Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative
Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesDemand Zone - dars.gov.et
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Cash Flow - tradingkey.com
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.470|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.390|Chg%:-0.080 - TradingKey
Galectin Therapeutics (NASDAQ:GALT) Breaks a Key Trend Line - Kalkine Media
GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress - Ad-hoc-news.de
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat
GALT stock gains support as Galectin Therapeutics keeps cash focus - Ad-hoc-news.de
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Galectin Therapeutics CMO Jamil Khurram disposes of 16,250 common shares for $83,284.5 - Bitget
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
$Galectin Therapeutics (GALT.US)$ to the moon stocktwits.com Galt Third time's the charm - Moomoo
$Galectin Therapeutics (GALT.US)$ - Moomoo
$Galectin Therapeutics (GALT.US)$ put CMO at the table with who at solar? - Moomoo
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Galectin Therapeutics (GALT) Gains 4.16% as Biotech Momentum BuildsTriple Top - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com South Africa
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):